Physician profile
Fletcher Peavy
NPI 1437869526
$4,499.12
in general payments reported to CMS, 2019-2025
25 companies · $1,473 in 2025
The $1,473 reported for 2025 was more than what 87% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,183 · 2024: $1,843 · 2025: $1,473.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,415 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,415.12 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $658.61 | 2023-2025 | Livdelzi, Epclusa |
| Abbvie INC. | $612.69 | 2023-2025 | |
| Janssen Biotech, INC. | $573.76 | 2023-2025 | Tremfya, Stelara, Simponi Aria |
| Ardelyx, INC. | $453.83 | 2023-2024 | Ibsrela |
| Genzyme Corporation | $391.30 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $331.26 | 2023-2025 | Xifaxan, Trulance, Relistor |
| Intra-Sana Laboratories | $250.00 | 2023-2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Takeda Pharmaceuticals U.S.A., INC. | $201.70 | 2023-2025 | Eohilia, Entyvio |
| Celltrion USA INC. | $178.24 | 2024-2025 | Vegzelma |
| Janssen Scientific Affairs, LLC | $138.18 | 2025 | Tremfya |
| Intercept Pharmaceuticals, INC. | $116.50 | 2023-2025 | Ocaliva |
| Ipsen Biopharmaceuticals, INC | $109.36 | 2025 | Iqirvo |
| Regeneron Healthcare Solutions, INC. | $82.87 | 2023-2024 | Dupixent |
| Merck Sharp & Dohme LLC | $59.00 | 2024 | Dificid |
| Qol Medical, LLC | $51.22 | 2024-2025 | Sucraid, Sucraid |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $51.22 | 2024 | |
| Orphalan INC | $48.63 | 2024-2025 | Cuvrior |
| Novo Nordisk INC | $33.01 | 2025 | Wegovy |
| Celgene Corporation | $31.23 | 2023 | Zeposia |
| Ironwood Pharmaceuticals, INC | $26.85 | 2024 | |
| Redhill Biopharma INC. | $24.17 | 2023 | |
| Lilly USA, LLC | $21.58 | 2025 | Omvoh |
| Amgen INC. | $20.12 | 2024 | Uplizna |
| Endogastric Solutions, INC | $18.26 | 2024 | Esophyx |
| Phathom Pharmaceuticals, INC. | $15.53 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fletcher Peavy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.